Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group (Q72472826)
Jump to navigation
Jump to search
scientific article published on 01 June 1994
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group |
scientific article published on 01 June 1994 |
Statements
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group (English)
C J Fisher
J F Dhainaut
S M Opal
J P Pribble
R A Balk
G J Slotman
T J Iberti
E C Rackow
M J Shapiro
R L Greenman